Browsing Tag
Relacorilant
4 posts
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Why did the FDA double down on rejecting Corcept’s flagship drug? Investors rattled
Corcept Therapeutics faces fresh regulatory headwinds as the FDA revises its relacorilant rejection letter, highlighting safety concerns and strategic missteps. Read more.
Corcept Therapeutics (NASDAQ: CORT) plunges as FDA rejects relacorilant for Cushing’s-related hypertension therapy
Corcept shares nosedive after FDA rejection of relacorilant for Cushing’s syndrome-related hypertension. Find out what this means for the company’s future.
Corcept Therapeutics submits FDA application for relacorilant to treat Cushing’s syndrome
Corcept Therapeutics Incorporated has taken a significant step in addressing the unmet needs of patients with hypercortisolism, commonly…